Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $8.04, up 4.42% on the session, giving a market capitalisation of $831.6M. On trailing twelve-month figures it carries a trailing P/E of -4.52, a net margin of 0.0%. Its beta of 0.40 implies it has historically moved less than the broad market.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Aura Biosciences, Inc. is most often compared with the following Healthcare names: